11 Jan 2019 Research

Leukaemia: Investigating stem cells to prevent cancer

What is this research looking at?

The development of effective treatments to prevent and eradicate leukaemia requires a better understanding of the mechanisms behind malignant (harmful) transformation and disease persistence during therapy.

Importantly, leukaemia development is associated with the acquisition of abnormal metabolic features, making cancer metabolism an attractive target for new therapeutic strategies.

Metabolism is closely associated to cell functions in normal and abnormal (malignant) tissues. By measuring metabolic heterogeneity in normal tissue (haemopoietic stem cells) and in cancer (leukaemia), I will determine whether distinct cell metabolic states are functionally connected to their potential for malignant transformation and therapy resistance.

I will test if malignant transformation and therapy resistance can be prevented or attenuated by targeting their metabolic dependencies. Results from the proposed research may lead to the development of new strategies for leukaemia eradication and prevention.

What could this mean for people with leukaemia?

This project investigates the metabolic features of stem cells in a bid to find out how to prevent them turning cancerous and to reduce resistance to treatment – this may lead to the development of new strategies for leukaemia eradication and prevention.

Related posts

An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care

10 November 2021

An urgent call from One Cancer Voice group of cancer charities for the Comprehensive Spending Review to deliver Government commitments to improve cancer survival & care

Leukaemia UK has joined with 50 other cancer charities in writing to the Prime Minister, Chancellor of the Exchequer and Secretary of State for Health and Social Care. We are calling on the Government to urgently deliver on commitments to improve cancer survival and care in the forthcoming Spending Review.

Dr Samanta Mariani recognised for her innovative research through Leukaemia UK John Goldman Fellowship and Olive Boles Innovation Award

11 August 2021

Dr Samanta Mariani recognised for her innovative research through Leukaemia UK John Goldman Fellowship and Olive Boles Innovation Award

We are delighted to announce the Leukaemia UK John Goldman Fellowship and Olive Boles Innovation Award has been awarded to Dr Samanta Mariani, in recognition of her innovative research that could contribute significantly to our understanding of leukaemia and other blood cancers.

Leukaemia UK announces John Goldman Fellows for 2022

8 November 2022

Leukaemia UK announces John Goldman Fellows for 2022

Leukaemia UK has awarded their prestigious John Goldman Fellow research grants to four outstanding early-career researchers seeking to advance our understanding of and ability to treat blood cancer. Leukaemia UK…

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

20 October 2023

Emerging leaders accolade for former Leukaemia UK John Goldman Fellows

Former Leukaemia UK John Goldman Fellows, Dr Matthew Blunt, University of Southampton and Dr Konstantinos Tzelepis, University of Cambridge have been recognised as ‘Emerging Leaders in Leukaemia’ by the major…